Lecture 9- Pharmacogenetics part II Flashcards
1
Q
cytochrome P450s
A
- major drug metabolizing enzymes
- many polymorphisms that affect drug efficacy or toxicity are in the CYP450
2
Q
CYP2D6 consequence
A
3
Q
nortriptyline
A
- 2nd generation tricyclic anti-depressant (TCA)
- Sensoval, Aventyl, Pamelor, Norpress, Allegron, Noritren, Nortrilen
- treats major depression
- inhibits reuptake of norepinephrine/noradrenaline and serotonin to a lesser extent
- narrow TI: therapeutic dose is close to toxic dose
- metabolized by CYP2D6
4
Q
Nortriptyline is metabolized by CYP2D6
A
poor drug metabolizer
- end up with toxic doses of the drug
- many side effects
- mild: drowsiness, dry mouth, nausea, headache
- serious: seizures, cardiac rhythm disturbances
ultra drug metabolizer
- inactivation of a drug rapidly so it is ineffective
5
Q
variation in drug metabolism of nortriptyline
A
6
Q
dosage of commonly used anti-psychotics is dependent on:
A
- dosage of commonly used anti-psychotics is dependent on the CYP2D6 genotype
7
Q
tamoxifen
A
- treatment for both early and advanced ER+ cancer (estrogen-receptor positive)
- pro-drug that is metabolized by CYP2D6 to its active metabolites (4-hydroxytamoxifen and endoxifen)
8
Q
CYP2D6 allele frequencies
A
9
Q
Plavix / clopidogrel
A
- treats blood clots
- pro-drug
- metabolized by CYP2C19 into its active form
- some CYP2C19 alleles result in a poor metabolizer of Plavix resulting in inactive drug
- inactive drug results in possible clots that could lead to myocardial infarction
10
Q
Warfarin/ coumadin
A
- anti-coagulant = “blood thinner”
- highly prescribed
- often dosing requires modification due to narrow TI
- metabolized by CYP2C9
11
Q
CYP2C9
A
- 3 allelic variants
- metabolizes warfarin
- CYP2C9*1 (wild type)
- CYP2C9*2
- CYP2C9*3
12
Q
VKORC1
A
- key rate limiting step in blood clotting
- target of warfarin
- has two major polymorphisms resulting in lower expression resulting in less warfarin dosing being required
- 1639G > A
- 1173C > T
13
Q
Warfarin related allele frequencies
A
14
Q
dose adjustment of warfarin
A
- based on combinations of CYP2C9 and VCORC1 genotype
15
Q
pharmacogenetics
A
- looks at specific allele differences within a single gene
- knowledge of target genes ahead of time
- direct link between SNP and phenotype
- require fairly small sample sizes to identify